Compare Extra Space Storage, Inc. (EXR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Repligen Corporation Common Stock — how do they compare? Extra Space Storage, Inc. trades at $135.18 (market cap $28.26B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Extra Space Storage, Inc. is far larger — about 2.5× Repligen Corporation Common Stock's market cap, and Extra Space Storage, Inc. pays a 4.85% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and Repligen Corporation Common Stock for 0 Days on average.
| EXR | RGEN | |
|---|---|---|
Market Cap | $28.26B | $11.14B |
Volume | 1,443,466 | 1,259,263 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $194.57 |
52-Week Low | $126.67 | $102.87 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $41.97B | $11.02B |
Dividend Yield | 4.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $134.06, up slightly by 0.01% today, with a neutral technical signal and bearish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38 billion in 2025, and net income reached $974 million, supported by a robust gross margin of 70.78%. Analyst consensus is evenly split between Buy and Hold, with a price target of $158.33, suggesting potential upside. Recent news highlights leadership transitions and steady dividend payments.
Outlook: EXR shows solid operational performance and financial flexibility, but faces risks from high leverage and softer housing demand. The stock's valuation metrics like P/E of 29.52 and EV/EBITDA of 17.35 indicate premium pricing. Investment opportunity lies in sustained earnings growth and dividend yield, while risks include interest rate sensitivity and competitive pressures in the REIT sector.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
